Aripiprazole

Producers shown on SFDA

(Record date:06/09/2021）

Producers shown on EP

(Quoted from EP website；record date:06/09/2021）

Producer:Topharman Shandong Co., Ltd.has passed the GMP inspection of China, the United States, the European Union and Japan. Tefaman has four production workshops and four independent clean areas with complete equipment and facilities, which can effectively control the chemical reaction from - 70 ℃ to 250 ℃.

Staff size:100-199 persons

Registered capital:RMB 10 million

Producer:Chongqing Pharmaceutical Research Institute Co., Ltd.was established in 1950 and is now wholly owned by Chongqing Yaoyou Pharmaceutical Co., Ltd. The total area of the company's Laboratory for R & D is more than 7000 square meters, equipped with international advanced analysis and testing equipment, and more than 1000 sets of various instruments and equipment. It has applied for more than 270 Chinese invention patents, 24 PCT patents and 37 foreign patents, and obtained 76 Chinese patent authorizations and 20 foreign patent authorizations.
Staff size:About 50 persons

Registered capital:RMB 55 million

Producer:The current business status of Chongqing Medical Engineering Institute Pharmaceutical Co., Ltd. is cancelled.
Staff size:/

Registered capital:RMB 135 million

Producer:Chengdu Hongda Pharmaceutical Co., Ltd. is subordinate to Kanghong pharmaceutical, which was established in 2007. It is a manufacturing industry. Its main industry is manufacturing, and its service fields are the production of API (aripiprazole, mosapride citrate, venlafaxine hydrochloride, pramipexole hydrochloride and dextropiclon, API of class II psychotropic drugs).
Staff size:50-99 persons

Registered capital:RMB 4 millio

Producer:Jiangsu Nhwa Pharmaceutical Co., Ltd.  founded in 1978 and listed on Shenzhen Stock Exchange in 2008, is a pharmaceutical enterprise integrating science, industry and trade.

It has three large pharmaceutical GMP production bases for APIs and preparations, covering a total area of more than 900 mu. The enterprise has national certified workshops for APIs, solid preparations, water injections and lyophilized powder injections, and more than 10 automatic production lines for tablets, capsules, water injections and powder injections. At present, there are 39 kinds of APIs, 300 tons / year; More than 100 kinds of Western medicine preparations, 4 billion tablets (tablets) of solid preparations per year and 100 million injections per year.

According to the enterprise development strategy, we have made great efforts to save energy, reduce consumption and protect the environment, passed the international environmental certification (ISO14000), vigorously developed the export business of API, carried out EU edmf and FDA certification, and strive to gain a place in the international market.

Staff size:About 5000 persons

Registered capital:RMB 1 billion 8 million

Producer:Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.is a leading R &D-driven pharmaceutical company in China. The company was listed on the Hong Kong Stock Exchange in June 2019

We have set up effective in house sales force with therapeutic area focus and strong academic promotion capabilities. We have established world class facilities and a manufacturing quality management system that compares with the cGMP requirements in China,  the United States and Japan. Our manufacturing systems have obtained cGMP certifications from the U.S. FDA and the Japanese PMDA,  and we plan to leverage our strong track record and experience to obtain additional quality system certifications and adopt advanced standards for entries into overseas markets. Our manufacturing quality management system enables us to produce all of our pharmaceutical products and the majority of our active pharmaceutical ingredients (APIs) in-h ouse.

Staff size:9000-9999 persons

Registered capital:RMB 1 million